An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Conclude your understanding of lymphoma with an in-depth look at its signs and symptoms, from common indicators to subtle clues.

Speaker : Dr Suvir Singh

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr Vijay Agarwal ,Dr. Ananth Pai ,Dr. Sai Vivek ,Dr. Harish P

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr. Harish P ,Dr. Sai Vivek ,Dr. Ananth Pai ,Dr Vijay Agarwal

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr. Vijay Agarwal ,Dr. Ananth Pai ,Dr. Sai Vivek ,Dr. Harish P

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr. Harish P ,Dr. Sai Vivek ,Dr. Ananth Pai ,Dr Vijay Agarwal

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr Vijay Agarwal ,Dr. Ananth Pai ,Dr. Sai Vivek ,Dr. Harish P

Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2

Explore the impact of CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, drawing insights from the pivotal PALOMA-2 study presented by Dr. Bhavna Parikh.

Speakers : Dr Bhavna Parikh

The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.

Discover the comprehensive impact of CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, with key insights from the PALOMA-2 study presented by Dr. Bhavna Parikh.

Speakers : Dr Bhavna Parikh

Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.

Explore the multifaceted advantages of CDK4/6 inhibitors in HR+/HER2- breast cancer, based on the PALOMA-2 study, in this insightful session with Dr. Bhavna Parikh.

Speakers : Dr Bhavna Parikh

An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.

A detailed discussion on the benefits of using CDK4/6 inhibitors in HR+/ HER2-aBC in clinical trials.

Speakers : Dr. Bhavna Parikh

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

The webinar gives insights into the role of pazopanib in managing renal cell carcinoma.

Speakers : Dr. Yogesh Kumar ,Dr. Pankaj Goyal ,Dr. Jatin Sarin ,Dr. Ankur Punia


Recommended News For You

Cardiorespiratory fitness lowers the risk of colon, lung, and prostate cancer in MEN and lowers mortality from these diseases.

Scientists develop scans that light up aggressive cancer tumors for better treatment

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma

Older Adults With Advanced Cancer Prioritize Quality of Life

Researchers discuss HER2-low and HER2-zero in breast cancer

New protocols, according to a study, allow many patients to safely return home one day after lung cancer surgery.

Three out of ten breast cancers detected between screenings, study finds

Recommended Articles For You

The Pros and Cons of Steroid Therapy for ITP 

AI in the War on Cancer: How Digital Tools are Revolutionizing Oncology 

Survival Rate Dynamics in Hematologic and Solid Malignancies 

Understanding Blood Dyscrasia: Symptoms, Causes and Treatment Options 
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Beyond What Is Visible in Myelofibrosis?

2.

FDA approves rivanetin as the first-line treatment for lung cancer.

3.

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

4.

New First-Line Option for Advanced ALK-Positive Lung Cancer

5.

Certain surgical gestures during prostate removal linked to better sexual function recovery

1.

Tremelimumab: A Potential Breakthrough in Cancer Treatment

2.

The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy

3.

Artificial Intelligence for Early Cancer Detection Leveraging Multi-Omics: A Comprehensive Review

4.

Harnessing Snake Venom in Hematology: From Toxins to Life-Saving Therapeutics

5.

Unlocking the Potential of SCD: A Comprehensive Guide to Diagnosis and Treatment

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII

2.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion

3.

Updates on Standard V/S High Risk Myeloma Treatment

4.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V

5.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot